BIVI - BIOVIE INC.

1.36
0.020   1.471%

Share volume: 30,569
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$1.34
0.02
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
24%
Profitability 19%
Dept financing 25%
Liquidity 16%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1.49%
1 Month
17.24%
3 Months
-14.47%
6 Months
-24.44%
1 Year
14.29%
2 Year
82.50%
Key data
Stock price
$1.36
P/E Ratio 
0.00
DAY RANGE
$1.29 - $1.36
EPS 
-$2.36
52 WEEK RANGE
$0.62 - $9.56
52 WEEK CHANGE
$24.77
MARKET CAP 
8.747 M
YIELD 
N/A
SHARES OUTSTANDING 
7.544 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
3.13
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$80,651
AVERAGE 30 VOLUME 
$105,892
Company detail
CEO: Cuong V. Do
Region: US
Website: bioviepharma.com
Employees: 10
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

BioVie Inc. engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trials for Alzheimer's, Parkinson's and multiple myeloma and prostate cancer.

Recent news